Merck Serono partners with Ono to treat cancer and MS

10/4/2011 | Genetic Engineering & Biotechnology News

Ono Pharmaceuticals and Merck Serono entered two agreements covering the former's ONO-4641, a midstage oral compound for multiple sclerosis, and the latter's Stimuvax, a late-stage immunotherapy for cancer. The first deal gives Merck Serono worldwide rights excluding Taiwan, South Korea and Japan to ONO-4641 for $18.75 million upfront plus milestone fees. For the second contract, Ono will pay Merck Serono about $6.7 million upfront for Japanese co-development and co-commercialization rights to Stimuvax.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA